SCHEMBL2063216

SCHEMBL2063216

COc1cc2c(Oc3ccc(CC(=O)Nc4ccc(F)cc4)cc3)ccnc2cc1OCCC(N)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.62
PDGFRA P16234 9/20 0.62
MET P08581 10/20 0.59
KIT P10721 3/20 0.59
RET P07949 2/20 0.59
DDR1 Q08345 2/20 0.59
CSF1R P07333 2/20 0.59
PDGFRB P09619 2/20 0.59
AXL P30530 3/20 0.59
MERTK Q12866 3/20 0.59
FLT4 P35916 2/20 0.59
FLT3 P36888 2/20 0.59
AURKA O14965 1/20 0.59
RIPK2 O43353 1/20 0.59
ABCB11 O95342 1/20 0.59
ABL1 P00519 1/20 0.59
EGFR P00533 1/20 0.59
ERBB2 P04626 1/20 0.59
NTRK1 P04629 1/20 0.59
LCK P06239 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063209 1.00 KDR (0.62) KDRPDGFRAMETKITRET
SCHEMBL2063128 0.94 MET (0.62) KDRPDGFRAMETKITRET
SCHEMBL2063125 0.94 MET (0.62) KDRPDGFRAMETKITRET
SCHEMBL2063516 0.93 MET (0.64) KDRPDGFRAMETKITRET
SCHEMBL2063513 0.93 MET (0.64) KDRPDGFRAMETKITRET
SCHEMBL2064010 0.92 PDGFRA (0.62) KDRPDGFRAMETKITRET
SCHEMBL2064006 0.92 PDGFRA (0.62) KDRPDGFRAMETKITRET
SCHEMBL2062936 0.90 KDR (0.60) KDRPDGFRAMETKITRET
SCHEMBL2063942 0.89 KDR (0.64) KDRPDGFRAMETKITRET
SCHEMBL2063937 0.89 KDR (0.64) KDRPDGFRAMETKITRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148531-B2 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2012-04-03 US disclosed
EP-1877383-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2011-09-07 EP disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed
EP-1877383-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY Chroma Therapeutics Limited (GB) 2008-01-16 EP disclosed
WO-2006117552-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 KDR 3088/4885PDGFRA 3858/4885MET 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.